A United Kingdom MedTech company, Glow Therapeutics and NeuralVillage Healthcare & Technology Ltd, have entered into a new Memorandum of Understanding, MoU, beginning an exploratory collaboration to deliver targeted support for people with dementia across Nigeria.
According to the press release signed by Japhet Kineze, the Founder and CEO of NeuralVillage, stated that under this MoU, Glow Therapeutics and NeuralVillage will work together to understand how the Harmoni Technology could be introduced into Nigeria through community and government pathways.
Kineze noted that Nigeria was home to more than 1.5 million people living with dementia. Families carry most of the day to day burden of care and support. There was a clear need for practical, accessible tools that can make life easier in the early and mid stages after diagnosis, especially for those struggling with Sundowning.
The statement disclosed that Nigeria’s healthcare system was built around 36 States and 774 Local Government Areas and these LGAs responsible for primary healthcare delivery were often the first line of support for vulnerable households.
It stated that this makes them a natural channel for distributing technology that helps families manage dementia at home.
It also stated that NeuralVillage hopes to bring deep on the ground insight into Nigeria’s public sector landscape and years of work across community health, neurological care and civic engagement as well as their understanding of how healthcare decisions flow at State and LGA level could be central to exploring how Harmoni can reach the people who need it.
While Glow Therapeutics brings the validated foundation behind Harmoni and the experience gained through work with care organisations and dementia support networks in the UK and beyond.
Founder and CEO of NeuralVillage, who shared his vision for Nigeria becoming a global home for Neuroscience Technology, urged the Federal Government to prioritize neurological care, focusing specifically on supporting local populations affected by dementia in Nigeria.
He explained that, “Due to the lack of quality access to neurotechnology devices, grassroots communities continue to suffer from numerous neurological conditions, as many primary healthcare centers were neglected and lack basic neurotechnology assessment tools.”
He stated that over the coming months both organisations will be mapping regulatory and operational pathways while identifying LGAs that may form the basis of a pilot explaining that the aim was to build a model that could support families across Nigeria and create a scalable route for accessible dementia support.
Also, Stuart Craig the Co-founder of Glow Therapeutics has expressed his confidence in the Nigerian Healthcare Market as foundation to become the light of an enabling environment for Neurotechnology companies in every stage to thrive using technology to tackling toughest challenges of numerous neurological issues faced by over Millions of people.
Stuart expressed confident that the Nigerian healthcare market has the foundation to become a leading environment for neurotechnology companies adding that his vision was for these companies, at every stage, to use technology to tackle the complex challenges of neurological issues currently faced by millions of Nigerians.
The statement added that both companies expressed their excitement of the MoU and look forward to sharing updates as the collaboration progresses.
